Predictive Biomarkers for Endocrine Therapy: Retrospective Study in Tamoxifen and Exemestane Adjuvant Multinational (TEAM) Trial
Abstract Background Aromatase inhibitors improve disease-free survival compared with tamoxifen in postmenopausal women with hormone receptor–positive breast cancer. The Tamoxifen and Exemestane Adjuvant Multinational (TEAM) trial compared exemestane monotherapy with sequential therapy of tamoxifen f...
Saved in:
Published in | JNCI : Journal of the National Cancer Institute Vol. 110; no. 6; pp. 616 - 627 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Oxford University Press
01.06.2018
|
Online Access | Get full text |
Cover
Loading…
Abstract | Abstract
Background
Aromatase inhibitors improve disease-free survival compared with tamoxifen in postmenopausal women with hormone receptor–positive breast cancer. The Tamoxifen and Exemestane Adjuvant Multinational (TEAM) trial compared exemestane monotherapy with sequential therapy of tamoxifen followed by exemestane. The trial failed to show a statistically significant difference between treatment arms. A robust translational program was established to investigate predictive biomarkers.
Methods
A tissue microarray was retrospectively constructed using a subset of patient tissues (n = 4631) from the TEAM trial (n = 9766). Immunohistochemistry was performed for biomarkers, classed into three groups: MAPK pathway, NF-kappa B pathway, and estrogen receptor (ER) phosphorylation. Expression was analyzed for association with relapse-free survival (RFS) at 2.5 and 10 years and treatment regimen using Kaplan-Meier curves and log-rank analysis. All statistical tests were two-sided.
Results
In univariate analysis, ER167 (hazard ratio [HR] = 0.71, 95% confidence interval [CI] = 0.59 to 0.85, P < .001), IKKα (HR = 0.74, 95% CI = 0.60 to 0.92, P = .005), Raf-1338 (HR = 0.64, 95% CI = 0.52 to 0.80, P < .001), and p44/42 MAPK202/204 (HR = 0.77, 95% CI = 0.64 to 0.92, P = .004) were statistically significantly associated with improved RFS at 10 years in patients receiving sequential therapy. Associations were strengthened when IKKα, Raf-1338, and ER167 were combined into a cumulative prognostic score (HR = 0.64, 95% CI = 0.52 to 0.77, P < .001). Patients with an all negative IKKα, Raf-1338, and ER167 score favored exemestane monotherapy (odds ratio = 0.56, 95% CI = 0.35 to 0.90). In multivariable analysis, the IKKα, Raf-1338, and ER167 score (P = .001) was an independent prognostic factor for RFS at 10 years in patients receiving sequential therapy.
Conclusions
The IKKα, Raf-1338, and ER167 score is an independent predictive biomarker for lower recurrence on sequential therapy. Negative expression may further offer predictive value for exemestane monotherapy. |
---|---|
AbstractList | Abstract
Background
Aromatase inhibitors improve disease-free survival compared with tamoxifen in postmenopausal women with hormone receptor–positive breast cancer. The Tamoxifen and Exemestane Adjuvant Multinational (TEAM) trial compared exemestane monotherapy with sequential therapy of tamoxifen followed by exemestane. The trial failed to show a statistically significant difference between treatment arms. A robust translational program was established to investigate predictive biomarkers.
Methods
A tissue microarray was retrospectively constructed using a subset of patient tissues (n = 4631) from the TEAM trial (n = 9766). Immunohistochemistry was performed for biomarkers, classed into three groups: MAPK pathway, NF-kappa B pathway, and estrogen receptor (ER) phosphorylation. Expression was analyzed for association with relapse-free survival (RFS) at 2.5 and 10 years and treatment regimen using Kaplan-Meier curves and log-rank analysis. All statistical tests were two-sided.
Results
In univariate analysis, ER167 (hazard ratio [HR] = 0.71, 95% confidence interval [CI] = 0.59 to 0.85, P < .001), IKKα (HR = 0.74, 95% CI = 0.60 to 0.92, P = .005), Raf-1338 (HR = 0.64, 95% CI = 0.52 to 0.80, P < .001), and p44/42 MAPK202/204 (HR = 0.77, 95% CI = 0.64 to 0.92, P = .004) were statistically significantly associated with improved RFS at 10 years in patients receiving sequential therapy. Associations were strengthened when IKKα, Raf-1338, and ER167 were combined into a cumulative prognostic score (HR = 0.64, 95% CI = 0.52 to 0.77, P < .001). Patients with an all negative IKKα, Raf-1338, and ER167 score favored exemestane monotherapy (odds ratio = 0.56, 95% CI = 0.35 to 0.90). In multivariable analysis, the IKKα, Raf-1338, and ER167 score (P = .001) was an independent prognostic factor for RFS at 10 years in patients receiving sequential therapy.
Conclusions
The IKKα, Raf-1338, and ER167 score is an independent predictive biomarker for lower recurrence on sequential therapy. Negative expression may further offer predictive value for exemestane monotherapy. BackgroundAromatase inhibitors improve disease-free survival compared with tamoxifen in postmenopausal women with hormone receptor-positive breast cancer. The Tamoxifen and Exemestane Adjuvant Multinational (TEAM) trial compared exemestane monotherapy with sequential therapy of tamoxifen followed by exemestane. The trial failed to show a statistically significant difference between treatment arms. A robust translational program was established to investigate predictive biomarkers. MethodsA tissue microarray was retrospectively constructed using a subset of patient tissues (n = 4631) from the TEAM trial (n = 9766). Immunohistochemistry was performed for biomarkers, classed into three groups: MAPK pathway, NF-kappa B pathway, and estrogen receptor (ER) phosphorylation. Expression was analyzed for association with relapse-free survival (RFS) at 2.5 and 10 years and treatment regimen using Kaplan-Meier curves and log-rank analysis. All statistical tests were two-sided. ResultsIn univariate analysis, ER167 (hazard ratio [HR] = 0.71, 95% confidence interval [CI] = 0.59 to 0.85, P < .001), IKKα (HR = 0.74, 95% CI = 0.60 to 0.92, P = .005), Raf-1338 (HR = 0.64, 95% CI = 0.52 to 0.80, P < .001), and p44/42 MAPK202/204 (HR = 0.77, 95% CI = 0.64 to 0.92, P = .004) were statistically significantly associated with improved RFS at 10 years in patients receiving sequential therapy. Associations were strengthened when IKKα, Raf-1338, and ER167 were combined into a cumulative prognostic score (HR = 0.64, 95% CI = 0.52 to 0.77, P < .001). Patients with an all negative IKKα, Raf-1338, and ER167 score favored exemestane monotherapy (odds ratio = 0.56, 95% CI = 0.35 to 0.90). In multivariable analysis, the IKKα, Raf-1338, and ER167 score (P = .001) was an independent prognostic factor for RFS at 10 years in patients receiving sequential therapy. ConclusionsThe IKKα, Raf-1338, and ER167 score is an independent predictive biomarker for lower recurrence on sequential therapy. Negative expression may further offer predictive value for exemestane monotherapy. Aromatase inhibitors improve disease-free survival compared with tamoxifen in postmenopausal women with hormone receptor-positive breast cancer. The Tamoxifen and Exemestane Adjuvant Multinational (TEAM) trial compared exemestane monotherapy with sequential therapy of tamoxifen followed by exemestane. The trial failed to show a statistically significant difference between treatment arms. A robust translational program was established to investigate predictive biomarkers. A tissue microarray was retrospectively constructed using a subset of patient tissues (n = 4631) from the TEAM trial (n = 9766). Immunohistochemistry was performed for biomarkers, classed into three groups: MAPK pathway, NF-kappa B pathway, and estrogen receptor (ER) phosphorylation. Expression was analyzed for association with relapse-free survival (RFS) at 2.5 and 10 years and treatment regimen using Kaplan-Meier curves and log-rank analysis. All statistical tests were two-sided. In univariate analysis, ER167 (hazard ratio [HR] = 0.71, 95% confidence interval [CI] = 0.59 to 0.85, P < .001), IKKα (HR = 0.74, 95% CI = 0.60 to 0.92, P = .005), Raf-1338 (HR = 0.64, 95% CI = 0.52 to 0.80, P < .001), and p44/42 MAPK202/204 (HR = 0.77, 95% CI = 0.64 to 0.92, P = .004) were statistically significantly associated with improved RFS at 10 years in patients receiving sequential therapy. Associations were strengthened when IKKα, Raf-1338, and ER167 were combined into a cumulative prognostic score (HR = 0.64, 95% CI = 0.52 to 0.77, P < .001). Patients with an all negative IKKα, Raf-1338, and ER167 score favored exemestane monotherapy (odds ratio = 0.56, 95% CI = 0.35 to 0.90). In multivariable analysis, the IKKα, Raf-1338, and ER167 score (P = .001) was an independent prognostic factor for RFS at 10 years in patients receiving sequential therapy. The IKKα, Raf-1338, and ER167 score is an independent predictive biomarker for lower recurrence on sequential therapy. Negative expression may further offer predictive value for exemestane monotherapy. |
Author | Dirix, Luc Y Quintayo, Mary-Anne Rea, Daniel W Bayani, Jane McMillan, Donald C Markopoulos, Christos Seynaeve, Caroline Roseweir, Antonia K van de Velde, Cornelis J H Dickson, Ashley Bennett, Lindsay Bartlett, John M S Horgan, Paul G Hasenburg, Annette Cheng, Kelvin Kieback, Dirk G Mallon, Elizabeth A Edwards, Joanne |
Author_xml | – sequence: 1 givenname: Antonia K surname: Roseweir fullname: Roseweir, Antonia K email: antonia.roseweir@glasgow.ac.uk organization: School of Medicine, University of Glasgow, Glasgow, UK – sequence: 2 givenname: Lindsay surname: Bennett fullname: Bennett, Lindsay organization: School of Medicine, University of Glasgow, Glasgow, UK – sequence: 3 givenname: Ashley surname: Dickson fullname: Dickson, Ashley organization: Institute of Cancer Sciences, University of Glasgow, Glasgow, UK – sequence: 4 givenname: Kelvin surname: Cheng fullname: Cheng, Kelvin organization: Institute of Cancer Sciences, University of Glasgow, Glasgow, UK – sequence: 5 givenname: Mary-Anne surname: Quintayo fullname: Quintayo, Mary-Anne organization: Ontario Institute of Cancer Research, MaRS Institute, Toronto, Canada – sequence: 6 givenname: Jane surname: Bayani fullname: Bayani, Jane organization: Ontario Institute of Cancer Research, MaRS Institute, Toronto, Canada – sequence: 7 givenname: Donald C surname: McMillan fullname: McMillan, Donald C organization: School of Medicine, University of Glasgow, Glasgow, UK – sequence: 8 givenname: Paul G surname: Horgan fullname: Horgan, Paul G organization: School of Medicine, University of Glasgow, Glasgow, UK – sequence: 9 givenname: Cornelis J H surname: van de Velde fullname: van de Velde, Cornelis J H organization: Leiden University Medical Centre, Leiden, the Netherlands – sequence: 10 givenname: Caroline surname: Seynaeve fullname: Seynaeve, Caroline organization: Erasmus MC Cancer Institute, Rotterdam, the Netherlands – sequence: 11 givenname: Annette surname: Hasenburg fullname: Hasenburg, Annette organization: University Hospital Mainz, Mainz, Germany – sequence: 12 givenname: Dirk G surname: Kieback fullname: Kieback, Dirk G organization: Helios Medical Centre, Schleswig, Germany – sequence: 13 givenname: Christos surname: Markopoulos fullname: Markopoulos, Christos organization: Athens University Medical School, Athens, Greece – sequence: 14 givenname: Luc Y surname: Dirix fullname: Dirix, Luc Y organization: St Augustinus Hospital, Antwerp, Belgium – sequence: 15 givenname: Daniel W surname: Rea fullname: Rea, Daniel W organization: University of Birmingham, Birmingham, UK – sequence: 16 givenname: Elizabeth A surname: Mallon fullname: Mallon, Elizabeth A organization: Department of Pathology, Queen Elizabeth University Hospital, Glasgow, UK – sequence: 17 givenname: John M S surname: Bartlett fullname: Bartlett, John M S organization: Ontario Institute of Cancer Research, MaRS Institute, Toronto, Canada – sequence: 18 givenname: Joanne surname: Edwards fullname: Edwards, Joanne organization: Institute of Cancer Sciences, University of Glasgow, Glasgow, UK |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/29917140$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kD1v2zAQhonCQe18TN0LTkWCQAlJiabVzQmcDyBBgkSdBYo8oXQlUiWlwN7y00NDTsfecsM99-LuOUQT6ywg9I2SC0ry9HJtlbnU6w3j_Aua0WxOEkYJn6AZIUwki4XIpugwhDWJlbPsK5qyPKeCZmSG3p89aKN68wb4yrhW-j_gA66dxyurnfLGAi5-g5fd9id-gd670MHIv_aD3mJjcSFbtzE1WCytxqsNtBB6GReXej28Sdvjx6HpjZW9cVY2-LRYLR_PcOGNbI7RQS2bACf7foR-3ayK67vk4en2_nr5kKiUiz5Jea44YYwCAwJcCgVZzQGyVFeaqnkcKUHrRcUF5ynwuaaMZTStKlEpLUl6hE7H3M67v0O8r2xNUNA08U43hJIRLijNs5xF9HxEVXw2eKjLzptoZltSUu6Ulzvl5ag80t_3wUPVgv7HfjqOwI8RcEP336QP8LKOEw |
CitedBy_id | crossref_primary_10_1016_j_bjoms_2019_11_025 crossref_primary_10_3390_cells7100176 crossref_primary_10_1186_s13058_023_01643_2 crossref_primary_10_1016_j_cellsig_2019_04_006 crossref_primary_10_1111_cbdd_14191 crossref_primary_10_3390_biomedicines11041060 crossref_primary_10_3390_ph16060783 |
ContentType | Journal Article |
Copyright | The Author 2017. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com 2017 |
Copyright_xml | – notice: The Author 2017. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com 2017 |
DBID | NPM AAYXX CITATION 7X8 |
DOI | 10.1093/jnci/djx255 |
DatabaseName | PubMed CrossRef MEDLINE - Academic |
DatabaseTitle | PubMed CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic PubMed |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1460-2105 |
EndPage | 627 |
ExternalDocumentID | 10_1093_jnci_djx255 29917140 10.1093/jnci/djx255 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | --- -E4 -~X .2P .I3 .XZ .ZR 08P 0R~ 1TH 29L 2WC 354 4.4 482 48X 5GY 5RE 5VS 5WD 70D 96U AABZA AACZT AAHTB AAJKP AAJQQ AAMVS AAOGV AAPNW AAPQZ AAPXW AARHZ AASNB AAUAY AAUQX AAVAP AAWTL ABCQX ABEUO ABIXL ABJNI ABKDP ABNHQ ABNKS ABOCM ABPEJ ABPPZ ABPTD ABQLI ABQNK ABXVV ABZBJ ACBMB ACGFO ACGFS ACGOD ACKOT ACNCT ACPRK ACUFI ACUTJ ACUTO ACYHN ADBBV ADEYI ADEZT ADGZP ADHKW ADHZD ADIPN ADJQC ADOCK ADQBN ADRIX ADRTK ADVEK ADYVW ADZXQ AEGPL AEJOX AEKSI AEMDU AENZO AEPUE AETBJ AEWNT AFAZI AFFNX AFFZL AFIYH AFOFC AFRAH AFXAL AGINJ AGKEF AGSYK AGUTN AHMBA AHXPO AIAGR AIJHB AJEEA ALMA_UNASSIGNED_HOLDINGS ALUQC APIBT APWMN ATGXG BAWUL BAYMD BCRHZ BEYMZ BTRTY BVRKM C45 CDBKE CS3 CZ4 DAKXR DIK DILTD DU5 D~K E3Z EBS EE~ EMOBN ENERS F5P F8P F9B FECEO FLUFQ FOEOM FOTVD FQBLK GAUVT GJXCC GX1 H13 H5~ HAR HW0 HZ~ IH2 IOX J21 JXSIZ KAQDR KBUDW KOP KQ8 KSI KSN L7B M-Z M49 MHKGH ML0 N9A NGC NOMLY NOYVH NU- OAUYM OAWHX OBH OCB OCZFY ODMLO ODZKP OGEVE OHH OJQWA OJZSN OK1 OPAEJ OVD OWPYF P2P PAFKI PEELM PQQKQ Q.- Q1. Q5Y R44 RD5 RHF RNS ROL ROX ROZ RUSNO RW1 RXO TCURE TEORI TJX TMA TR2 TWZ UDS UPT VVN W8F WH7 WOQ X7H YAYTL YKOAZ YQT YXANX ZKX ZRR ZY1 ~91 ~H1 NPM AAYXX ABEJV AHMMS CITATION 7X8 |
ID | FETCH-LOGICAL-c357t-359c50221e2e0e5a7ce4f5ee43dbd1c6022c71f8b57553e56d122413bb7bcda03 |
ISSN | 0027-8874 |
IngestDate | Wed Dec 04 03:28:01 EST 2024 Fri Dec 06 01:31:26 EST 2024 Wed Oct 16 00:48:22 EDT 2024 Wed Sep 11 04:51:44 EDT 2024 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 6 |
Language | English |
License | This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/about_us/legal/notices) http://academic.oup.com/journals/pages/about_us/legal/notices |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c357t-359c50221e2e0e5a7ce4f5ee43dbd1c6022c71f8b57553e56d122413bb7bcda03 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-News-3 content type line 23 |
OpenAccessLink | https://academic.oup.com/jnci/article-pdf/110/6/616/25041899/djx255.pdf |
PMID | 29917140 |
PQID | 2057119492 |
PQPubID | 23479 |
PageCount | 12 |
ParticipantIDs | proquest_miscellaneous_2057119492 crossref_primary_10_1093_jnci_djx255 pubmed_primary_29917140 oup_primary_10_1093_jnci_djx255 |
PublicationCentury | 2000 |
PublicationDate | 20180601 2018-06-01 |
PublicationDateYYYYMMDD | 2018-06-01 |
PublicationDate_xml | – month: 06 year: 2018 text: 20180601 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | JNCI : Journal of the National Cancer Institute |
PublicationTitleAlternate | J Natl Cancer Inst |
PublicationYear | 2018 |
Publisher | Oxford University Press |
Publisher_xml | – name: Oxford University Press |
References | Ross-Innes ( key 20180618194126_djx255-B18) 2012; 481 Dhawan ( key 20180618194126_djx255-B19) 2002; 277 Coates ( key 20180618194126_djx255-B3) 2007; 25 Park ( key 20180618194126_djx255-B16) 2005; 18 Bartlett ( key 20180618194126_djx255-B14) 2011; 29 Chia ( key 20180618194126_djx255-B7) 2012; 18 Cheng ( key 20180618194126_djx255-B12) 2017; 70 The national institute of health and care excellence (NICE) ( key 20180618194126_djx255-B5) 2009 Coombes ( key 20180618194126_djx255-B4) 2007; 369 Lannigan ( key 20180618194126_djx255-B17) 2003; 68 Bennett ( key 20180618194126_djx255-B11) 2017; 140 Shaikh ( key 20180618194126_djx255-B1) 2012; 2012 McShane ( key 20180618194126_djx255-B15) 2005; 93 Campbell ( key 20180618194126_djx255-B8) 2016; 115 McGlynn ( key 20180618194126_djx255-B10) 2009; 15 Murphy ( key 20180618194126_djx255-B13) 2011; 18 Arimidex TAoiCTG ( key 20180618194126_djx255-B2) 2008; 9 Carlson ( key 20180618194126_djx255-B6) 2013; 141 van de Velde ( key 20180618194126_djx255-B9) 2011; 377 |
References_xml | – volume: 15 start-page: 1487 issue: 4 year: 2009 ident: key 20180618194126_djx255-B10 article-title: Ras/Raf-1/MAPK pathway mediates response to tamoxifen but not chemotherapy in breast cancer patients publication-title: Clin Cancer Res. contributor: fullname: McGlynn – year: 2009 ident: key 20180618194126_djx255-B5 contributor: fullname: The national institute of health and care excellence (NICE) – volume: 277 start-page: 7920 issue: 10 year: 2002 ident: key 20180618194126_djx255-B19 article-title: A novel NF-kappa B-inducing kinase-MAPK signaling pathway up-regulates NF-kappa B activity in melanoma cells publication-title: J Biol Chem. contributor: fullname: Dhawan – volume: 25 start-page: 486 issue: 5 year: 2007 ident: key 20180618194126_djx255-B3 article-title: Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: Update of study BIG 1-98 publication-title: J Clin Oncol. contributor: fullname: Coates – volume: 93 start-page: 387 issue: 4 year: 2005 ident: key 20180618194126_djx255-B15 article-title: REporting recommendations for tumour MARKer prognostic studies (REMARK) publication-title: Br J Cancer. contributor: fullname: McShane – volume: 18 start-page: R1 issue: 1 year: 2011 ident: key 20180618194126_djx255-B13 article-title: Clinical significance of estrogen receptor phosphorylation publication-title: Endocr Relat Cancer. contributor: fullname: Murphy – volume: 2012 start-page: 849592 year: 2012 ident: key 20180618194126_djx255-B1 article-title: Adjuvant hormonal therapy in postmenopausal women with breast cancer: Physician's choices publication-title: Int J Breast Cancer. contributor: fullname: Shaikh – volume: 18 start-page: 71 issue: 1 year: 2005 ident: key 20180618194126_djx255-B16 article-title: Formation of an IKKalpha-dependent transcription complex is required for estrogen receptor-mediated gene activation publication-title: Mol Cell. contributor: fullname: Park – volume: 115 start-page: 967 issue: 8 year: 2016 ident: key 20180618194126_djx255-B8 article-title: The combined endocrine receptor in breast cancer, a novel approach to traditional hormone receptor interpretation and a better discriminator of outcome than ER and PR alone publication-title: Br J Cancer. contributor: fullname: Campbell – volume: 140 start-page: 1633 issue: 7 year: 2017 ident: key 20180618194126_djx255-B11 article-title: High IKKalpha expression is associated with reduced time to recurrence and cancer specific survival in oestrogen receptor (ER)-positive breast cancer publication-title: Int J Cancer. contributor: fullname: Bennett – volume: 481 start-page: 389 issue: 7381 year: 2012 ident: key 20180618194126_djx255-B18 article-title: Differential oestrogen receptor binding is associated with clinical outcome in breast cancer publication-title: Nature. contributor: fullname: Ross-Innes – volume: 377 start-page: 321 issue: 9762 year: 2011 ident: key 20180618194126_djx255-B9 article-title: Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): A randomised phase 3 trial publication-title: Lancet. contributor: fullname: van de Velde – volume: 141 start-page: 13 issue: 1 year: 2013 ident: key 20180618194126_djx255-B6 article-title: The impact of the Oncotype Dx breast cancer assay in clinical practice: A systematic review and meta-analysis publication-title: Breast Cancer Res Treat. contributor: fullname: Carlson – volume: 29 start-page: 1531 issue: 12 year: 2011 ident: key 20180618194126_djx255-B14 article-title: Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: A prospectively powered pathology study in the Tamoxifen and Exemestane Adjuvant Multinational trial publication-title: J Clin Oncol. contributor: fullname: Bartlett – volume: 68 start-page: 1 issue: 1 year: 2003 ident: key 20180618194126_djx255-B17 article-title: Estrogen receptor phosphorylation publication-title: Steroids. contributor: fullname: Lannigan – volume: 9 start-page: 45 issue: 1 year: 2008 ident: key 20180618194126_djx255-B2 article-title: Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial publication-title: Lancet Oncol. contributor: fullname: Arimidex TAoiCTG – volume: 70 start-page: 782 issue: 5 year: 2017 ident: key 20180618194126_djx255-B12 article-title: The relationship between oestrogen receptor-alpha phosphorylation and the tumour microenvironment in patients with primary operable ductal breast cancer publication-title: Histopathology. contributor: fullname: Cheng – volume: 18 start-page: 4465 issue: 16 year: 2012 ident: key 20180618194126_djx255-B7 article-title: A 50-gene intrinsic subtype classifier for prognosis and prediction of benefit from adjuvant tamoxifen publication-title: Clin Cancer Res. contributor: fullname: Chia – volume: 369 start-page: 559 issue: 9561 year: 2007 ident: key 20180618194126_djx255-B4 article-title: Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): A randomised controlled trial publication-title: Lancet. contributor: fullname: Coombes |
SSID | ssj0000924 |
Score | 2.360392 |
Snippet | Abstract
Background
Aromatase inhibitors improve disease-free survival compared with tamoxifen in postmenopausal women with hormone receptor–positive breast... Aromatase inhibitors improve disease-free survival compared with tamoxifen in postmenopausal women with hormone receptor-positive breast cancer. The Tamoxifen... BackgroundAromatase inhibitors improve disease-free survival compared with tamoxifen in postmenopausal women with hormone receptor-positive breast cancer. The... |
SourceID | proquest crossref pubmed oup |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 616 |
Title | Predictive Biomarkers for Endocrine Therapy: Retrospective Study in Tamoxifen and Exemestane Adjuvant Multinational (TEAM) Trial |
URI | https://www.ncbi.nlm.nih.gov/pubmed/29917140 https://search.proquest.com/docview/2057119492 |
Volume | 110 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLbKkBAviDsbNyPtATRlay52Ut66rmgDbeKhk_YW1Y6jpaIJStNR8cQf5b9wju0kDYVxeYmqNHYVn6_Hx8ff-UzIrmJeyvuJD5FbKJ2Ay8SJFBdOJCKeyinubWmC7Bk_Pg_eX7CLXu_7GmtpWYl9-fWXdSX_Y1W4B3bFKtl_sGzTKdyAz2BfuIKF4fpXNv5Y4jaLJv8cZsUcmTal1lfYG-dJIbGwDykVKBtgiG9VWdSllZpBqIv-JtN5scpSZWjJ45WaKwwZ8bDm2RIC7WpPV-k2aUOISSfj4SnmEyb4kp349mx0orMMa4GuplHWjUeIsrLlKLQbPgv1RWWlFTQosFisycAe6uKhJoewaIk_R1kjETBcXNab1JquoKwXU5-urLq4TW64UUvCuq5oct2hezDJRuagn31lfHjA-w6sZFnHyVvybLbhsrnL12Z_bpQKNiYWI7o1yyWCIpmtPCMu_JNW92-evEFuok4jHu1wdPKhDRQGnhUJN-9gy0ehgwNsfmAadwKmThHmxlpIx0STu-SOtTEdGmTeIz2V3ye3Ti1d4wH51gKUtgClMNq0ASi1AH1LO_CkGp40y2kDTwrwpC08aQ1P2oEnfY3gfEM1NB-S83fjyejYsUd-ONJnYeX4bCAZhJWu8lRfsWkoVZAypQI_EYkrOXwlQzeNBKwymK8YT8zOsBChkMm07z8iW3mRqyeEKhHyFOWXJKpcuoGAFqn0JCxowBiRt01263GNPxtll9gwMvwYhz82w79NXsKYX__Eq9oeMfhm3HCDQSiWi9iDxZDrDoIB_NhjY6imIwgDXRTL3Plj_0_J7fav8YxsVeVSPYdIuBIvNJ5-AAvJuWM |
link.rule.ids | 314,780,784,27924,27925 |
linkProvider | Flying Publisher |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Predictive+Biomarkers+for+Endocrine+Therapy%3A+Retrospective+Study+in+Tamoxifen+and+Exemestane+Adjuvant+Multinational+%28TEAM%29+Trial&rft.jtitle=JNCI+%3A+Journal+of+the+National+Cancer+Institute&rft.au=Roseweir%2C+Antonia+K&rft.au=Bennett%2C+Lindsay&rft.au=Dickson%2C+Ashley&rft.au=Cheng%2C+Kelvin&rft.date=2018-06-01&rft.pub=Oxford+University+Press&rft.issn=0027-8874&rft.eissn=1460-2105&rft.volume=110&rft.issue=6&rft.spage=616&rft.epage=627&rft_id=info:doi/10.1093%2Fjnci%2Fdjx255&rft.externalDocID=10.1093%2Fjnci%2Fdjx255 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0027-8874&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0027-8874&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0027-8874&client=summon |